Extended Data Fig. 1: Maternal anesthesia method impacts maternal-fetal transmission of WAY-161503 and ChP activation.
From: Choroid plexus apocrine secretion shapes CSF proteome during mouse brain development
(A) Isofluorane inhibits E16.5 Fos induction. No anesthesia control n = 7, WAY n = 6. 2-4% vaporized isofluorane control n = 7, WAY n = 7. Ketamine/xylazine control n = 4, WAY n = 4. Isofluorane to ketamine/xylazine transition control n = 5, WAY n = 5. (B) qPCR validation of Htr2c knockout mouse lines. N = 7 wild-type and 5 KO embryos. (C) WAY-161503 does not induce activity-dependent gene expression in ChP from Htr2c knockout mouse line, n = 3 embryos/condition. (D) Representative images of RNAscope validation of Htr2c knockout in LV ChP. Scale bars 200 µm. (E) Urethane maintains WAY-161503-induced Fos. IP ketamine/xylazine, no surgery control n = 3, WAY n = 3. IP urethane/ketamine, abdominal incision, internal uterine horn control n = 3, WAY n = 4. IP urethane/ketamine, full mock setup control n = 3, WAY n = 2. Data Presentation: All data presented as mean ± SEM. P values from two-way ANOVA with Sidak correction for (A), (C), and (E) and from two-tailed unpaired t-test for (B).
